Immunotherapy for Prostate Cancer: Walk, Don't Run
- 1 September 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (25), 4035-4037
- https://doi.org/10.1200/jco.2009.22.2299
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate CancerJournal of Clinical Oncology, 2009
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSFCancer Research, 2009
- Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancerCancer, 2008
- Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancerNature Clinical Practice Oncology, 2008
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systemsJCI Insight, 2007
- PART V. Modulation of Antitumor Vaccine StrategiesPreclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma TherapyCritical Reviews in Immunology, 2007
- Differential proteomic alterations between localised and metastatic prostate cancerBritish Journal of Cancer, 2006
- Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trialsEuropean Journal Of Cancer, 2006
- Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerJournal of Clinical Oncology, 2006
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004